Lack of over-expression of T cell receptor Vβ5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls

Journal of Neuroimmunology

Volumn 84, Issue 1, 1998, Pages 7-13

  Afshar, Ghazaleh ^a   Muraro, Paolo A ^a,b   McFarland, Henry F ^a   Martin, Roland ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

CD4 positive T lymphocytes; HLA DR2 antigens; Multiple sclerosis; Myelin basic proteins; T cell receptors

Indexed keywords

HLA DR ANTIGEN; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; IMMUNOREGULATION; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; T LYMPHOCYTE;

ADULT; AGED; FEMALE; GENES, T-CELL RECEPTOR BETA; HLA-DR2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0032054172     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00215-4     Document Type: Article

References (26)

1. Acha-Orbea H., Steinman L., McDevitt H.O. T cell receptors in murine autoimmune diseases. Annu. Rev. Immunol. Annu. Rev. Immunol. 7:1989;371-406.
2. Bourdette D.N., Whitham R.H., Chou Y.K., Morrison W.Y., Atherton J., Kenny C., Liefeld D., Hashim G.A., Offner H., Vandenbark A.A. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides. J. Immunol. 152:1994;2510-2519.
3. Deibler G.E., Martenson R.E., Kies M.W. Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species. Prep. Biochem. 2:1972;139-165.
4. Fritz R.B., Skeen M.J., Chou C.H., Garcia M., Egorov I.K. Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. J. Immunol. 134:1985;2328-2332.
5. Giegerich G., Pette M., Meinl E., Epplen J.T., Wekerle H., Hinkkanen A. Diversity of T cell receptor alpha and beta chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes. Eur. J. Immunol. 22(3):1992;753-758.
6. Gold D.P., Smith R.A., Golding A.B., Morgan E.E., Dafashy T., Nelson J., Smith L., Diveley J., Laxer J.A., Richieri S.P., Carlo D.J., Brostoff S.W., Wilson D.B. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCR Vβ6 CDR2 peptide. J. Neuroimmunol. 76:1997;29-38.
7. Hafler D.A., Saadeh M.G., Kuchroo V.K., Milford E., Steinman L. TCR usage in human and experimental demyelinating disease. Immunol. Today. 17(4):1996;152-159.
8. Hall M.A., Lanchbury J.S. Healthy human T-cell receptor beta-chain repertoire: Quantitative analysis and evidence for V-beta-related effects on CDR3 structure and diversity. Hum. Immunol. 43:1995;207-218.
9. Joshi N., Usuku K., Hauser S.L. The T-cell response to myelin basic protein in familial multiple sclerosis: Diversity of fine specificity, restricting elements, and T-cell receptor usage. Ann. Neurol. 34:1993;385-393.
10. Kotzin B.L., Karuturi S., Chou Y.K., Lafferty J., Forrester J.M., Better M., Nedwin G.E., Offner H., Vandenbark A.A. Preferential T-cell receptor Vβ-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc. Natl. Acad. Sci. USA. 88:1991;9161-9165.
11. Ling N., Esch F., Bohlen P., Brazeau P., Wehrenberg W.B., Guilleman R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: Growth hormone-releasing factor. Proc. Natl. Acad. Sci. USA. 81:1984;4302-4306.
12. Martin R., McFarland H.F. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit. Rev. Clin. Lab. Sci. 32:1995;121-182.
13. Martin R., Howell M.D., Jaraquemada D., Flerlage M., Richert J., Brostoff S., Long E.O., McFarlin D.E., McFarland H.F. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J. Exp. Med. 173(1):1991;19-24.
14. Martin R., Utz U., Coligan J.E., Richert J.R., Flerlage M., Robinson E., Stone R., Biddison W.E., McFarlin D.E., McFarland H.F. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J. Immunol. 148:1992;1359-1366.
15. Meinl E., Weber F., Drexler K., Morelle C., Ott M., Saruhan-Direskeneli G., Goebels N., Ertl B., Jechart G., Giegerich G. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J. Clin. Invest. 92:1993;2633-2643.
16. *0401) subjects is associated with a restricted T cell receptor repertoire. J. Clin. Invest. 100:1997;339-349.
17. Musette P., Bequet D., Delarbre C., Gachelin G., Kourilsky P., Dormont D. Expansion of a recurrent V beta 5.3+ T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients. Proc. Natl. Acad. Sci. USA. 93:1996;12461-12466.
18. Offner H., Hashim G.A., Vandenbark A.A. T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis. Science. 251:1991;430-432.
19. Oksenberg J.R., Panzara M.A., Begovich A.B., Mitchell D., Erlich H.A., Murray R.S., Shimonkevitz R., Sherritt M., Rothbard J., Bernard C.C., Steinman L. Selection for T-cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 362:1993;68-70.
20. Utz U., Banks D., Jacobson S., Biddison W.E. Analysis of the T-Cell Receptor Repertoire of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax-Specific CD8+ Cytotoxic T Lymphocytes from Patients with HTLV-1-Associated Diseases: Evidence for Oligoclonal Expansions. J. Virol. 70:1996;843-851.
21. Vandenbark A.A., Hashim G., Offner H. Immunization with a synthetic T-cell receptor V-region peptide against experimental autoimmune encephalomyelitis. Nature. 341:1989;541-544.
22. Vandenbark A.A., Chou Y.K., Whitman R., Mass M., Buenafe A., Liefeld D., Kavanagh D., Cooper S., Hashim G.A., Offner H. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial. Nature Med. 2:1996;1109-1115.
23. Vandevyver C., Mertens N., van den Elsen P., Medaer R., Raus J., Zhang J. Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence. Eur. J. Immunol. 25:1995;958-968.
24. Wilson D.B., Golding A.B., Smith R.A., Dafashy T., Nelson J., Smith L., Carlo D.J., Brostoff S.W., Gold D.P. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell utilization in CSF cell populations. J. Neurimmunol. 76:1997;15-28.
25. Wucherpfennig K.W., Ota K., Endo N., Seidman J.G., Rosenzweig A., Weiner H.L., Hafler D.A. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science. 248:1990;1016-1019.
26. Zamvil S.S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev Immunol. 8:1990;579-621.